DOCSLIB.ORG

The Future of Genomic Medicine VII Thursday, March 6 and Friday, March 7, 2014 • Scripps Seaside Forum • La Jolla, California

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Future of Genomic Medicine VII Thursday, March 6 and Friday, March 7, 2014 • Scripps Seaside Forum • La Jolla, California The Future of Genomic Medicine VII Thursday, March 6 and Friday, March 7, 2014 • Scripps Seaside Forum • La Jolla, California Presented in partnership with AAAS/Science Translational Medicine Conference Highlights Dear Colleague, • Voice of the patient represented throughout the conference In collaboration with AAAS/Science Translational Medicine we • Renowned faculty representing the invite you to another exciting two day program on Thursday, March country’s leading institutions • Multiple panel discussion segments 6 and Friday, March 7, 2014 in beautiful San Diego, California. with ample question and answer time This year’s program will again be held at Scripps Seaside Forum. with faculty • Additional networking opportunities The 7th Future of Genomic Medicine conference will be the Educational Objectives next iteration of taking genomic knowledge to transform the • Demonstrate the unmet needs of medicine today with respect to more daily practice of medicine. To do this, we have patients present targeted, individualized prevention and their story of how genomics affected their medical status, and treatments. have an international faculty of experts in genomics, science and • Discuss the opportunities of the genome, proteome, metabolome discovery to medical journalism, and the life science industry provide critical change medical practice as it exists today. perspective. This year we will be paying particular attention to • Assess how changes and advances in technology are rapidly ushering in a whole genomics of undiagnosed and rare diseases, cancer (a disease of the array of new pathways for individualized genome), newborn and fetal genomics. Furthermore, we will delve medicine of the future. into the hot topics of pharmacogenomics, the microbiome, the • Explore specific strategies in cancer, idiopathic and pharmacogenomic futuristic genomics of health span and longevity. For the first time we have interventions. assembled a remarkable panel of science journalists and editors Target Audience to discuss the issues about what is being published in peer review • Physicians journals (including open access) and in the lay press related to • Health care professionals of all disciplines interested in the future of medicine, genomic medicine. The overarching goal of the conference is to especially with respect to individualized spearhead efforts to use genomic knowledge to change medicine therapies • Human geneticists and make it far more precise and individualized. • Genomic scientists • Researchers We look forward to your participation and another successful conference. Eric J. Topol, MD Course Director About Scripps Scripps Translational Science Institute (STSI), aims to replace For more information on the Scripps Translational Science Institute, the status-quo of one-size-fits-all-medicine with individualized visit www.stsiweb.org. health care that is based on the known genetic factors influencing health and disease and that takes advantage of advances in digital Scripps Health, a nonprofit health care system based in San Diego, technology for real-time health monitoring. California, includes more than 2,600 affiliated physicians and over 13,000 employees at five acute-care hospital campuses, home Since its founding in 2006 by Scripps Health, STSI has been health care services and a network of clinics, physician offices and distinguished by its leadership in translational genomics and for outpatient centers. Scripps is committed to contributing to the future harnessing digital, or wireless, medical technology for health of medicine through its clinical research trials, graduate medical monitoring of individual patients. In addition, it is the only member of education and continuing medical education programs. the National Institutes of Health’s Clinical and Translational Science More information can be found at www.scripps.org. Award (CTSA) consortium that is not affiliated with a university. For more information on Scripps Health, visit www.scripps.org. STSI hybridizes The Scripps Research Institute (TSRI)‘s considerable biomedical science expertise with Scripps Health’s exceptional patient care and clinical research. As a translational bridge between TSRI and Scripps Health, STSI fosters innovative programs and methodology, provides an optimal setting for training and education and accelerates the conduct of studies that will have the greatest potential impact on the practice of health care in the clinic and the community. Faculty Course Director Al Gore Michael Pellini, MD Former Vice President of the United States President and Chief Executive Officer Eric J. Topol, MD Foundation Medicine Director, Scripps Translational Science Institute Harry Greenspun, MD Cambridge, Massachusetts Chief Academic Officer, Scripps Health Senior Advisor Professor of Genomics Healthcare Transformation & Technology Heidi L. Rehm, PhD, FACMG The Scripps Research Institute Deloitte Center for Health Solutions Chief Laboratory Director for Molecular Medicine La Jolla, California Deloitte LLP Partners Healthcare Center for Personalized Genetic Medicine Planning Committee Chris Gunter, PhD Geneticist Assistant Professor of Pathology Cinnamon S. Bloss, PhD Owner, Girlscientist Consulting Harvard Medical School Director of Social Sciences and Bioethics Atlanta, Georgia Jessica Richman Assistant Professor, Scripps Translational Science Founder and CEO Institute, Scripps Health & Hakon Hakonarson, MD, PhD uBiome The Scripps Research Institute Director, Center for Applied Genomics La Jolla, California Associate Professor of Pediatrics Jay Shendure, MD, PhD Department of Pediatrics and Division of Genetics Assistant Professor of Genome Sciences Ali Torkamani, PhD Director of Genome Informatics The Children’s Hospital of Philadelphia University of Washington, School of Medicine and Drug Discovery University of Pennsylvania School of Medicine Seattle, Washington Scripps Translational Science Institute Philadelphia, Pennsylvania Magdalena Skipper, PhD Assistant Professor of Molecular and Experimental Jeffrey Hammerbacher, PhD Senior Editor, Biology, London Medicine, The Scripps Research Institute Assistant Professor Nature Publishing Group La Jolla, California Genetics and Genomic Sciences Michael Specter Conference Faculty Mount Sinai Hospital Staff writer New York, New York The New Yorker Russ B. Altman, MD, PhD Howard J. Jacob, PhD Professor of Bioengineering, Genetics, J. Craig Venter, PhD Director, Human and Molecular Genetics Center and Medicine Founder, Chairman and Chief Executive Officer Warren P. Knowles Chair of Genetics Chairman, Department of Bioengineering J. Craig Venter Institute Director, Biomedical Informatics Training Program Professor, Department of Physiology & Pediatrics San Diego, California Medical College of Wisconsin Past-President (2000-2001) Bert Vogelstein, MD International Society of Computational Biology Vice Chair of Research, Department of Pediatrics Howard Hughes Medical Institute Investigator Stanford University Children’s Hospital of Wisconsin Johns Hopkins University Stanford, California Milwaukee, Wisconsin Baltimore, Maryland Nir Barzilai, MD Katrina L. Kelner, PhD The Ingeborg and Ira Leon Rennert Chair Editor Anne E. Wojcicki of Aging Research Science Translational Medicine Chief Executive Officer and Co-Founder, 23andMe Professor of Medicine and Molecular Genetics Mountain View, California Muin J. Khoury, MD, PhD Director, Institute for Aging Research Director, Office of Public Health Genomics Carl Zimmer, PhD Albert Einstein College of Medicine Centers for Disease Control and Prevention Columnist, The New York Times Bronx, New York Atlanta, Georgia Arthur L. Beaudet, MD Henry and Emma Meyer Chair in Leonid Kruglyak, PhD Molecular Genetics Department of Biological Chemistry Professor, Department of Molecular and Human University of California, Los Angeles Genetics Los Angeles, California Baylor College of Medicine Elaine R. Mardis, PhD Houston, Texas Professor, Genetics and Molecular Microbiology Zubin Damania, MD Co-Director of The Genome Institute Director, Healthcare Development Washington University School of Medicine Downtown Project LLC St. Louis, Missouri Las Vegas, Nevada Frank McCormick, PhD, FRS Sarah-Jane Dawson, FRACP, PhD Associate Dean University of Cambridge and the Cancer Research University of California, San Francisco UK Cambridge Institute School of Medicine United Kingdom David A. Wood Distinguished Professorship David Epstein of Tumor Biology and Cancer Research Author, THE SPORTS GENE: The Science San Francisco, California of Extraordinary Athletic Performance Robert Nussbaum, MD Andrew Feinberg, MD, MPh Professor, Department of Medicine Daniel Coit Gilman Scholar Chief, Division of Medical Genetics Chief, Division of Molecular Medicine Holly Smith Distinguished Professorship in Johns Hopkins University School of Medicine Science and Medicine Baltimore, Maryland University of California, San Francisco San Francisco, California Program Thursday, March 6, and Friday, March 7, 2014 Thursday, March 6, 2014 Afternoon Session I: Moving Genomics to the Clinic 7:30 a.m. Registration and Breakfast 1:00 p.m. J. Craig Venter, PhD 8:00 a.m. Welcome and Opening Remarks 1:40 p.m. Interview and Q & A with Eric Topol, MD Eric J. Topol, MD, and and Vice President Al Gore Chris VanGorder, FACHE 2:10 p.m. Break, View Exhibits and Networking President and Chief Executive Officer 2:40 p.m. Heidi L. Rehm, PhD, FACMG Scripps Health 3:00 p.m. Muin J. Khoury, MD, PhD 8:15 a.m. Patient/Family # 1 3:20 p.m. Afternoon
Load more

Recommended publications
  • The Bio Revolution: Innovations Transforming and Our Societies, Economies, Lives
    The Bio Revolution: Innovations transforming economies, societies, and our lives economies, societies, our and transforming Innovations Revolution: Bio The The Bio Revolution Innovations transforming economies, societies, and our lives May 2020 McKinsey Global Institute Since its founding in 1990, the McKinsey Global Institute (MGI) has sought to develop a deeper understanding of the evolving global economy. As the business and economics research arm of McKinsey & Company, MGI aims to help leaders in the commercial, public, and social sectors understand trends and forces shaping the global economy. MGI research combines the disciplines of economics and management, employing the analytical tools of economics with the insights of business leaders. Our “micro-to-macro” methodology examines microeconomic industry trends to better understand the broad macroeconomic forces affecting business strategy and public policy. MGI’s in-depth reports have covered more than 20 countries and 30 industries. Current research focuses on six themes: productivity and growth, natural resources, labor markets, the evolution of global financial markets, the economic impact of technology and innovation, and urbanization. Recent reports have assessed the digital economy, the impact of AI and automation on employment, physical climate risk, income inequal ity, the productivity puzzle, the economic benefits of tackling gender inequality, a new era of global competition, Chinese innovation, and digital and financial globalization. MGI is led by three McKinsey & Company senior partners: co-chairs James Manyika and Sven Smit, and director Jonathan Woetzel. Michael Chui, Susan Lund, Anu Madgavkar, Jan Mischke, Sree Ramaswamy, Jaana Remes, Jeongmin Seong, and Tilman Tacke are MGI partners, and Mekala Krishnan is an MGI senior fellow.
    [Show full text]
  • UBIOME, INC., Debtor. Chapter 11 Case No. 19
    Case 19-11938-LSS Doc 2 Filed 09/04/19 Page 1 of 42 IN IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Chapter 11 UBIOME, INC.,1 Case No. 19-_____ (___) Debtor. DECLARATION OF CURTIS G. SOLSVIG III IN SUPPORT OF THE DEBTOR’S CHAPTER 11 PETITION AND REQUESTS FOR FIRST DAY RELIEF I, Curtis G. Solsvig III, hereby declare under penalty of perjury, pursuant to section 1746 of title 28 of the United States Code, as follows: 1. I am the Acting Chief Executive Officer (the “Acting CEO”) of uBiome, Inc., the debtor and debtor in possession in the above-captioned chapter 11 case (the “Debtor” or “uBiome”). 2. On or about May 24, 2019, I was originally retained by uBiome to provide financial consulting services, and on June 27, 2019,2 I was appointed by a special committee of the board to serve as the Debtor’s Acting CEO. As a Managing Director for Goldin Associates, LLC (“Goldin”), I have more than 30 years of experience in the turnaround industry, both as a restructuring advisor and as an interim manager, including chief executive officer or chief restructuring officer. My experience includes fiduciary and non-fiduciary roles in the restructurings or liquidations of, among others, Lily Robotics, Inc., Real Industries, Quiksilver, Borders Books, Restoration Hardware, Manischewitz Foods, Atari, Cornerstone Propane and Ports America. I have extensive expertise in the fund management business, including portfolio 1 The Debtor and the last four digits of its taxpayer identification number is: uBiome, Inc. (0019). The Debtor’s headquarters is located at 360 Langton Street, Suite 301, San Francisco, CA 94103.
    [Show full text]
  • Philosophy and Practice of Bioethics Across and Between Cultures
    Philosophy and Practice of Bioethics across and between Cultures Editors: Takao Takahashi, Nader Ghotbi & Darryl R. J. Macer Eubios Ethics Institute 2019 ii Philosophy and Practice of Bioethics Across and Between Cultures Eubios Ethics Institute Christchurch Tsukuba Science City Bangkok Cataloging-in-Publication data Philosophy and Practice of Bioethics across and between Cultures / Takahashi, Takao / Ghotbi, Nader / Macer, Darryl R.J. Christchurch, N.Z.: Eubios Ethics Institute ©2019. Copyright © 2019 Eubios Ethics Institute All rights reserved. The copyright for the complete publication is held by the Eubios Ethics Institute. The material may be used in education provided the copies are provided free of charge. No part of this publication may be reproduced for commercial use, without the prior written permission of the Eubios Ethics Institute. http://www.eubios.info/ 1 v. 22 Chapters. ISBN 978-0-908897-33-9 1. Bioethics. 2. Medical ethics. 3. Ethics. 4. Peace. 5. Philosophy. 6. Justice. 7. Disaster. 8. Information technology ethics. 9. Japan. 10. Asian Studies. 2. I. Takahashi, Takao, 1948. II. Ghotbi, Nader, 1967. III. Macer, Darryl Raymund Johnson, 1962. IV. Eubios Ethics Institute. V. Title (Philosophy and Practice of Bioethics across and between Cultures). The Eubios Ethics Institute is a nonprofit group that aims to stimulate the discussion of ethical issues, and how we may use new technology in ways consistent with "good life". An important part of this dialogue is to function as an information source for those with similar concerns. Publications are available through the website www.eubios.info, and refer to the ordering guidelines in this book. The views expressed in this book do not necessarily represent the views of the Eubios Ethics Institute, nor the editors.
    [Show full text]
  • Dr. Zubin Damania, MD Cyber Events for July
    NH-ISAC Monthly Newsletter –TLP White July 2017 Announcing our Keynote Speaker for our Fall Summit! Top 10 Health Related Dr. Zubin Damania, MD Cyber Events for July: You may not know the name of one of the most talented and Fancy Bear Hackers Steal, Dump innovative forces in healthcare but there is a high probability Photos of Cosmetic Surgery Clinic that you have seen one of his video parodies about health. Patients This is because Zubin Damania, M.D., goes under the alias, ZDogg MD. HHS Targeting Outdated Regs In Dr. Zubin Damania, MD, is an internist and the founder of Wake of Damning Cybersecurity Turntable Health, an innovative healthcare startup that was Report, WannaCry part of an ambitious urban revitalization movement spear headed by Zappos.com CEO Tony Hsieh. During his 10-year Industroyer: Biggest threat to industrial control systems since hospitalist career at Stanford, he won clinical teaching awards while simultaneously Stuxnet maintaining a shadow career performing stand-up comedy for medical audiences worldwide. His videos and live Facebook shows, created under the pseudonym ZDoggMD, have gone HHS-OCR Cyber Quick Response epidemically viral with a quarter of a billion views on YouTube and Facebook. Checklist In Las Vegas, he implemented an innovative model of healthcare delivery that promotes FDA Plans to Address Risks of wellness at both the individual and community level. Turntable Health, a membership model Digital Health Products team-based primary care ecosystem, was a ground-up effort to get healthcare right by restoring the primacy of the human relationship, a concept they call “Health 3.0”.
    [Show full text]
  • Interview with Dr. Zubin Damania (Zdoggmd)
    Fixing Healthcare Episode 1 Transcript: Interview with Dr. Zubin Damania (ZDoggMD) Jeremy Corr: Hello and welcome to the inaugural episode of Fixing Healthcare with Dr. Robert Pearl and Jeremy Corr. I am one of your hosts, Jeremy Corr. I am also the host of New Books in Medicine. I have with me my co-host Doctor Robert Pearl. Robert is the former CEO of the Permanente Group, the largest physician group in the United States, responsible for caring for Kaiser Permanente members on both the East and West Coast. He is a Forbes contributor, a professor at both Stanford University School of Medicine and Business, and is the author of the best selling book "Mistreated: Why We Think We're Getting Good Healthcare-- and Why We're Usually Wrong." Robert Pearl: Hello everyone, and welcome to our monthly podcast aimed at addressing the failures of the current American healthcare system, and finding solutions to make it once again the best in the world. We are very excited to have you join us in this quest. Jeremy Corr: For 40 years our nation's political and medical leaders have talked about fixing the American healthcare system. No one has succeeded, yet. We need a hero. Our guests are the top leaders and thinkers in healthcare. Robert Pearl: The show's format is simple, a guest will have 10 minutes to present the roadmap for fixing American healthcare's biggest problems. From there, Jeremy and I will scrutinize the plan, posing questions that challenge our guests, and help our listeners separate real solutions from hype.
    [Show full text]
  • The Future of Genomic Medicine IX Thursday, March 3 and Friday, March 4, 2016 • Scripps Institution of Oceanography • La Jolla, California
    The Future of Genomic Medicine IX Thursday, March 3 and Friday, March 4, 2016 • Scripps Institution of Oceanography • La Jolla, California Presented in partnership with AAAS/Science Translational Medicine Course Introduction Conference Highlights • Voice of the patient represented Course Overview throughout the conference In collaboration with AAAS/Science Translational Medicine we invite you to • Renowned faculty representing the another exciting two day program on Thursday, March 3 and Friday, March country’s leading institutions • Multiple panel discussion segments 4, 2016 in beautiful San Diego, California. The 2016 program will again be with ample question and answer time with faculty held at Scripps Institution of Oceanography. • Additional networking opportunities The 9th Future of Genomic Medicine conference will be the next iteration Educational Objectives of taking genomic knowledge to transform the daily practice of medicine. After attending this activity, participants should be able to: To do this, we have patients present their story of how genomics affected • Demonstrate the unmet needs of their medical status, and have an international faculty of experts in genomics, medicine today with respect to more targeted, individualized prevention science and medical journalism, and the life science industry provide critical and treatments. perspective. This year we will be paying particular attention to the exciting • Discuss the opportunities of the genome, proteome, metabolome area of genomic editing to treat particular diseases, cancer (a disease of the discovery to change medical practice as it exists today. genome), and the genomics of rare and unknown diseases. Furthermore, we • Assess how changes and advances in will delve into to the hot topics of the microbiome, genomic-guided drug technology are rapidly ushering in a whole array of new pathways for therapies and genomic analytics.
    [Show full text]
  • Sponsorship & Advertising Opportunities
    NEW ORLEANS, LA NOVEMBER 9 –12, 2019 SPONSORSHIP & ADVERTISING OPPORTUNITIES Pam Russell Exhibits Coordinator — Meetings & Convention Department American Association for Respiratory Care Email: [email protected] | www.aarc.org Phone: 972.243.2272 INTRODUCTION A FIRST CLASS EVENT AARC Congress attracts top respiratory therapists, physicians, healthcare providers and companies from around the U.S. and over 25+ countries. CONGRESS DAYS Saturday, November 9 through Tuesday, November 12 EXHIBIT HALL DAYS AND HOURS Saturday, November 9 Enhance Your Exhibit With Sponsorships 10:30am - 4:00pm Congress sponsorships extend your presence beyond Sunday, November 10 the exhibit booth. With sponsorships you’ll reach the 9:30am - 3:00pm active-buying respiratory care professional throughout the convention center...in the hotels...even back at Monday, November 11 their hospitals after the show. 9:30am - 2:00pm SPONSORSHIPS THAT FIT YOUR GOALS AND BUDGET Choose an Individual Choose Multiple Design Your Sponsorship Sponsorships Own Sponsorship 1Showcase your brand and 2Multiple sponsorships 3Let us know if you have boost exhibit hall booth make big impressions for a sponsorship idea for traffic with an individual your brand and reassure the AARC Congress. sponsorship. AARC buyers that your brand The AARC is always Congress sponsorships is an industry leader. open to new ideas. display your brand strength Guarantee your Congress Contact: Doug Laher in the industry and brand dominance and at [email protected] or increase the awareness of odds of increasing your 972-406-4698 your company’s purpose. booth traffic. ALL RATES ARE SUBJECT TO CHANGE WITHOUT NOTICE. 2 TABLE OF CONTENTS: SPONSORSHIP PROSPECTUS EVENT SPONSORSHIP ADVERTISEMENT – DIGITAL AARC Welcome Party ....................
    [Show full text]
  • Fixing Healthcare Podcast Transcript Interview with Zubin Damania
    Fixing Healthcare Podcast Transcript Interview with Zubin Damania Jeremy Corr: Hello, and welcome to season five of the Fixing Healthcare podcast. I am one of your hosts, Jeremy Corr. I'm also the host of the popular New Books in Medicine podcast. With me is Dr. Robert Pearl. For 18 years, Robert was the CEO of the Permanente Medical Group, the nation's largest physician group. He is currently a Forbes contributor, a professor at both the Stanford University School of Medicine and Business, and author of the bestselling book Mistreated: Why We Think We're Getting Good Health Care—and Why We're Usually Wrong. Robert Pearl: Hello everyone, and welcome to the new season of our monthly podcast aimed at addressing the failures of the American healthcare system, and finding solutions to make it, once again, the best in the world. In this, our fifth season, we turn to the culture of medicine and the impact it is having on patients and healthcare providers. Jeremy Corr: Today we’ll have the opportunity to interview Dr. Zubin Damania, best known to his fans as ZDoggMD. He hosts the internet’s number one medical news and entertainment show, reaching millions of people every week. He is a leading voice for patient-centered healthcare, focusing on prevention and team-based medicine. He graduated from the University of California School of Medicine and completed his residency in Internal Medicine at Stanford, where he later worked a hospitalist and taught on the faculty. He, along with Zappos CEO Tony Hsieh, started Turntable Health in Las Vegas as an alternative to the broken American healthcare system.
    [Show full text]
  • Understanding Users Information Needs and Collaborative Sensemaking of Human Microbiome Data
    Understanding Users Information Needs and Collaborative Sensemaking of Human Microbiome Data ANONYMOUS AUTHOR(S)∗ Recent years are seeing a sharp increase in the availability of personal ’omic’ (e.g. genomes, microbiomes) data to non-experts through direct-to-consumer testing kits. While the scientific understanding of human -omic information is evolving, the interpretation of the data may impact well-being of users and relevant others, and therefore poses challenges and opportunities for CSCW research. We identify the information, interaction, and sense-making needs of omic data users, within the broader context of social omics - the sharing and collaborative engagement with data and interpretation. Analyzing users’ discussions on Reddit’s r/HumanMicrobiome, we identified seven user needs: reviewing an annotated report, comparing microbiome data, tracking changes, receiving personalized actionable information, curating information, controlling information, and documenting and sharing self experiments. We highlight the ways in which users interact with each other to collaboratively make sense of the data. We conclude with design implications, including tools for better communication with care providers, and for symptom-centered sharing and discussion. CCS Concepts: • Human-centered computing → Empirical studies in collaborative and social com- puting. Additional Key Words and Phrases: online communities, microbiome, collaborative sensemaking ACM Reference Format: Anonymous Author(s). 2019. Understanding Users Information Needs and Collaborative Sensemaking of Human Microbiome Data. 1, 1 (April 2019), 22 pages. https://doi.org/10.1145/nnnnnnn.nnnnnnn 1 INTRODUCTION In recent years, there has been a sharp increase in the availability of personal ’omic’ data (e.g. genomes, microbiomes) to non-experts through direct-to-consumer testing kits.
    [Show full text]
  • Conference Is a Winner!
    VOL 17 • NO 2 SPRING, MAY/JUNE 2018 SUPPORTING THE HUMAN RIGHT TO A DEATH WITH DIGNITY www.finalexitnetwork.org Dying in the Americas 2018 Conference Is a Winner! t was, by nearly every measure and every account, a great success. Typical was this unsolicited remark from a partic- I ipant, “I was so inspired by the speakers and the attendees. The conference content was delightfully jam-packed, speakers were so interesting, evening events were connecting…” Sponsored and conducted by Final Exit Network, the “Dy- ing in the Americas 2018” conference brought together about 150 activists, academicians, and interested people, along with YouTube’s favorite mortician, a rapping physician, and Canadian right-to-die revolutionaries for 3-1/2 days in an outskirt of Las Vegas. Attendees were informed, entertained, and motivated by a line-up of stellar speakers. In this issue of the newsletter we present impressions of the conference—not summaries of all talks or highlights of the pro- gram, just a collection of impressions. They say what happens in Vegas stays in Vegas. In this in- stance, there is hope that the conference messages radiate far beyond Nevada’s borders. Canada, Latin America, and the U.S. were represented in the hemisphere-wide conference. Friday Keynote Speaker, Dr. Zubin Damania (top), also known as rap artist ZdoggMD, talked about “Healthcare 3.0,” and a new vision of how healthcare can be more responsive to patient’s wishes. Above center, John Abraham (Arizona FEN affiliate leader) took part in one of many robust audience conversations. Bottom photo, Dr.
    [Show full text]
  • Temporary Policy Emergency Provisions For
    MEDICAL POLICY Temporary Policy Emergency Provisions for: Direct-to-Consumer and Over-the- Counter Testing Effective Date: 6/1/2021 Medical Policy Number: 73 Medical Policy Committee Approved Date: 8/18; 8/19; 2/2020; 7/2020; 9/2020; 2/2021 6/1/2021 Medical Officer Date See Policy CPT/HCPCS CODE section below for any prior authorization requirements NEED AND DURATION OF EMERGENCY PROVISIONS 1. Need for the temporary Provisions: COVID-19 public health emergency 2. Documents or source relied upon: Families First Coronavirus Response Act (FFCRA) and the Coronavirus Aid, Relief, and Economic Security (CARES) Act1-4 3. Initial Effective Date: 8/1/2020 4. Re-review dates: 9/23/2020; 11/30/2020; 2/1/2021; 3/31/2021; 6/1/2021 5. Termination Date: 12/31/2021 6. Next Reassessment Date determined at Companies sole discretion: 12/30/2021 POLICY ADDENDUM Applies To: Commercial, ASO, and Medicare Effective for Dates of Service: 2/26/2021 onward COVID-19 Public Health Emergency Under section 6001 of the Families First Coronavirus Response Act (FFCRA) and section 4201 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, health plans must provide coverage of in vitro diagnostic products for the detection or diagnosis of SARS-CoV-2 or COVID-19 that are approved by the U.S. Food and Drug Administration (FDA).1,2 On June 23, 2020, the Department of Labor (DOL), Department of Health and Human Services (DHHS), and the Department of the Treasury (collectively, the Departments) jointly released an FAQ around the FFCRA and CARES act implementation.3 This FAQ (see question 4) indicates that COVID-19 tests intended for at-home testing must be covered.
    [Show full text]
  • IP Pragmatics Microbiome White Paper June 2017
    JUNE 2017 EXPLOITING THE MICROBIOME: MARKET DEVELOPMENTS AND INTELLECTUAL PROPERTY LANDSCAPE Primary Authors: Scott McKellar, Kyriakos Tzafestas & Sophie Brayne Sector Lead: Ronnie Georghiou IP Pragmatics Limited London | Edinburgh | Sydney www.ip-pragmatics.com 2 | P a g e CONTENTS Contents ..................................................................................................................................... 2 Executive Summary .................................................................................................................... 4 Introduction ................................................................................................................................ 5 Market Overview ...................................................................................................................... 10 Human Health and Wellbeing .............................................................................................. 10 Therapeutics ..................................................................................................................... 13 Food & Nutrition ............................................................................................................... 17 Diagnostics ........................................................................................................................ 18 Animal Health ....................................................................................................................... 23 Sustainable Farming ........................................................................................................
    [Show full text]